Prosecution Insights
Last updated: April 19, 2026

Omeros Corporation

7 pending office actions

Portfolio Summary

7
Total Pending OAs
0
Final Rejections
7
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18523203 ANTIBODIES SPECIFICALLY BINDING TO MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS WEN, SHARON X 1641 Non-Final OA Nov 29, 2023
18451632 Methods and Compositions for Treating Cancer PAK, MICHAEL D 1674 Non-Final OA Aug 17, 2023
18176155 HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITORY ANTIBODY FORMULATIONS, KITS, AND METHODS KIM, YUNSOO 1641 Non-Final OA Feb 28, 2023
18168192 COMPOSITIONS FOR INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION SKELDING, ZACHARY S 1644 Non-Final OA Feb 13, 2023
18152536 Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation SKELDING, ZACHARY S 1644 Non-Final OA Jan 10, 2023
17823793 TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS VISHNYAKOVA, ELENA VLADIMIROVNA 1691 Non-Final OA Aug 31, 2022
17665176 BIOMARKER FOR ASSESSING THE RISK OF DEVELOPING ACUTE COVID-19 AND POST-ACUTE COVID-19 MCCOLLUM, ANDREA K 1674 Non-Final OA Feb 04, 2022

Managing Omeros Corporation's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month